- $17.26bn
- $19.45bn
- $2.86bn
Revvity falls after Q3 revenue misses estimates
Health tech firm Revvity misses Q3 revenue estimates, announces $1 bln buyback program
Life sciences firms climb after Pfizer drug pricing agreement with US government
U.S. RESEARCH ROUNDUP-Autozone, Cognex, Royal Gold
U.S. RESEARCH ROUNDUP-Cadence Design Systems, Coinbase Global, Kinsale Capital Group
U.S. STOCKS ON THE MOVE-CervoMed, Talen Energy, PACCAR
U.S. STOCKS ON THE MOVE-CervoMed, Talen Energy, PACCAR
Revvity trims 2025 profit forecast as China policy changes hit diagnostics demand (updated)
Revvity Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-PagerDuty, CervoMed, Talen Energy
Revvity trims 2025 profit forecast on soft demand for diagnostics in China
U.S. STOCKS ON THE MOVE-Tesla, Nike, Pfizer
Revvity falls after cutting annual profit forecast
Brief: Revvity Q2 Adjusted EBIT USD 191.802 Million Vs. IBES Estimate USD 187.2 Million
Mettler-Toledo lowers annual profit forecast on tariff impact
U.S. RESEARCH ROUNDUP-Domino's Pizza, Prologis, Springworks Therapeutics
U.S. STOCKS ON THE MOVE-Nvidia, Sabre, Biohaven
U.S. STOCKS ON THE MOVE-Marriott, Wells Fargo, Insulet
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook (updated)